NASDAQ:CORI - Corium International Stock Price, Price Target & More

$10.08 +0.08 (+0.80 %)
(As of 04/26/2018 11:06 AM ET)
Previous Close$10.00
Today's Range$9.88 - $10.25
52-Week Range$4.04 - $13.93
Volume32,250 shs
Average Volume276,751 shs
Market Capitalization$362.68 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59

About Corium International (NASDAQ:CORI)

Corium International logoCorium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.

Receive CORI News and Ratings via Email

Sign-up to receive the latest news and ratings for CORI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CORI
CUSIPN/A
Phone650-298-8255

Debt

Debt-to-Equity Ratio5.91%
Current Ratio1.40%
Quick Ratio1.34%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$31.86 million
Price / Sales11.43
Cash FlowN/A
Price / CashN/A
Book Value$0.45 per share
Price / Book22.40

Profitability

EPS (Most Recent Fiscal Year)($1.64)
Net Income$-47,790,000.00
Net Margins-148.07%
Return on Equity-403.15%
Return on Assets-62.88%

Miscellaneous

Employees213
Outstanding Shares36,120,000

How to Become a New Pot Stock Millionaire

Corium International (NASDAQ:CORI) Frequently Asked Questions

What is Corium International's stock symbol?

Corium International trades on the NASDAQ under the ticker symbol "CORI."

How were Corium International's earnings last quarter?

Corium International (NASDAQ:CORI) released its quarterly earnings results on Thursday, February, 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.06. The biopharmaceutical company earned $9.32 million during the quarter, compared to analyst estimates of $7.48 million. Corium International had a negative return on equity of 403.15% and a negative net margin of 148.07%. View Corium International's Earnings History.

What price target have analysts set for CORI?

5 equities research analysts have issued 1-year price targets for Corium International's stock. Their predictions range from $10.00 to $14.00. On average, they anticipate Corium International's share price to reach $13.00 in the next twelve months. View Analyst Ratings for Corium International.

What are Wall Street analysts saying about Corium International stock?

Here are some recent quotes from research analysts about Corium International stock:
  • 1. According to Zacks Investment Research, "Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. " (4/16/2018)
  • 2. Cantor Fitzgerald analysts commented, "Important update includes expectation to file donepezil patch NDA with pilot BE data. On 3/26, in conjunction with a presentation at an investor conference, CORI provided a corporate update (slide deck here). Likely of great interest to investors is the expectation that the NDA will be filed with data from the pilot bioequivalence (BE) study (see Exhibit 1 in this report)." (3/27/2018)

Are investors shorting Corium International?

Corium International saw a increase in short interest in March. As of March 15th, there was short interest totalling 2,873,611 shares, an increase of 81.0% from the February 28th total of 1,587,260 shares. Based on an average daily volume of 570,194 shares, the short-interest ratio is presently 5.0 days. Currently, 11.0% of the company's stock are short sold.

Who are some of Corium International's key competitors?

Who are Corium International's key executives?

Corium International's management team includes the folowing people:
  • Mr. Peter D. Staple, Pres, CEO & Director (Age 66)
  • Mr. Robert S. Breuil, Chief Financial Officer (Age 56)
  • Dr. Joseph J. Sarret, Chief Bus. Officer (Age 51)
  • Mr. Timothy D. Sweemer CPA, Chief Accounting Officer, VP of Admin. & Sec.
  • Dr. Parminder Singh, CTO & VP of R&D (Age 54)

Has Corium International been receiving favorable news coverage?

News articles about CORI stock have trended somewhat positive on Thursday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Corium International earned a news sentiment score of 0.11 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 47.48 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Corium International's major shareholders?

Corium International's stock is owned by many different of institutional and retail investors. Top institutional shareholders include RIDGEBACK CAPITAL INVESTMENTS L.P. (5.20%). Company insiders that own Corium International stock include David Greenwood, Eric Bjerkholt, Healthcare Master Fun Broadfin, Joseph J Sarret, Life Sciences Maste Perceptive, Parminder Singh, Perceptive Advisors Llc and Timothy D Sweemer. View Institutional Ownership Trends for Corium International.

How do I buy shares of Corium International?

Shares of CORI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corium International's stock price today?

One share of CORI stock can currently be purchased for approximately $10.08.

How big of a company is Corium International?

Corium International has a market capitalization of $362.68 million and generates $31.86 million in revenue each year. The biopharmaceutical company earns $-47,790,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Corium International employs 213 workers across the globe.

How can I contact Corium International?

Corium International's mailing address is 235 CONSTITUTION DRIVE, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-298-8255 or via email at [email protected]


MarketBeat Community Rating for Corium International (CORI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  254 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  434
MarketBeat's community ratings are surveys of what our community members think about Corium International and other stocks. Vote "Outperform" if you believe CORI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Corium International (NASDAQ:CORI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Corium International in the last 12 months. Their average twelve-month price target is $13.00, suggesting that the stock has a possible upside of 28.97%. The high price target for CORI is $14.00 and the low price target for CORI is $10.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.00$13.00$13.00$13.1429
Price Target Upside: 28.97% upside21.16% upside30.65% upside21.13% upside

Corium International (NASDAQ:CORI) Consensus Price Target History

Price Target History for Corium International (NASDAQ:CORI)

Corium International (NASDAQ:CORI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/27/2018Cantor FitzgeraldReiterated RatingBuy$14.00HighView Rating Details
2/9/2018HC WainwrightSet Price TargetBuy$14.00LowView Rating Details
12/26/2017Needham & Company LLCLower Price TargetBuy -> Buy$16.00 -> $14.00HighView Rating Details
10/29/2017Jefferies GroupSet Price TargetBuy$10.00N/AView Rating Details
7/7/2017WBB SecuritiesUpgradeBuy$13.00LowView Rating Details
4/18/2017FBR & CoReiterated RatingOutperform -> Outperform$12.00 -> $13.00LowView Rating Details
1/4/2017Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Corium International (NASDAQ:CORI) Earnings History and Estimates Chart

Earnings by Quarter for Corium International (NASDAQ:CORI)

Corium International (NASDAQ:CORI) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.47 EPS
Next Year EPS Consensus Estimate: $-1.31 EPS

Corium International (NASDAQ CORI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/8/2018Q1 2018($0.43)($0.37)$7.48 million$9.32 millionViewN/AView Earnings Details
11/16/2017Q4 2017($0.43)($0.36)$9.57 million$9.44 millionViewN/AView Earnings Details
8/3/2017Q3 2017($0.30)($0.43)$8.71 million$8.11 millionViewListenView Earnings Details
5/11/2017Q2 2017($0.3720)($0.42)$6.05 million$7.35 millionViewN/AView Earnings Details
2/13/2017Q1 2017($0.42)($0.46)$8.07 million$7.00 millionViewN/AView Earnings Details
11/21/2016Q4 2016($0.39)($0.42)$9.08 million$7.92 millionViewN/AView Earnings Details
8/4/2016Q3($0.42)($0.34)$8.38 million$10.61 millionViewN/AView Earnings Details
5/10/2016Q2($0.37)($0.47)$8.64 million$6.96 millionViewListenView Earnings Details
2/8/2016Q1($0.35)($0.42)$8.93 million$7.54 millionViewN/AView Earnings Details
11/12/2015Q4($0.4530)($0.42)$9.47 million$9.27 millionViewListenView Earnings Details
7/29/2015Q3($0.3730)($0.33)$10.45 million$10.60 millionViewListenView Earnings Details
5/7/2015Q2 2015($0.35)($0.40)$9.73 million$11.29 millionViewN/AView Earnings Details
2/10/2015Q115($0.29)($0.37)$10.42 million$9.77 millionViewN/AView Earnings Details
11/17/2014Q4 2014($0.32)($0.51)$10.26 million$11.07 millionViewN/AView Earnings Details
8/12/2014Q3 2014($0.17)($0.28)$12.22 million$10.18 millionViewN/AView Earnings Details
5/13/2014Q2 2014($0.18)($0.24)$10.58 million$10.72 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Corium International (NASDAQ:CORI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Corium International (NASDAQ CORI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 30.80%
Institutional Ownership Percentage: 88.58%
Insider Trading History for Corium International (NASDAQ:CORI)
Institutional Ownership by Quarter for Corium International (NASDAQ:CORI)

Corium International (NASDAQ CORI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/18/2018Life Sciences Maste PerceptiveMajor ShareholderBuy510,000$12.54$6,395,400.00View SEC Filing  
1/16/2018Perceptive Advisors LlcMajor ShareholderBuy50,350$11.83$595,640.50View SEC Filing  
11/17/2017Healthcare Master Fun BroadfinMajor ShareholderSell500,000$10.96$5,480,000.00View SEC Filing  
11/2/2017Healthcare Master Fun BroadfinMajor ShareholderSell150,000$11.05$1,657,500.00View SEC Filing  
10/4/2017Healthcare Master Fun BroadfinMajor ShareholderSell218,100$11.01$2,401,281.00View SEC Filing  
8/22/2017Parminder SinghInsiderSell30,415$7.59$230,849.8530,762View SEC Filing  
8/17/2017Parminder SinghInsiderSell32,000$7.61$243,520.00View SEC Filing  
8/17/2017Timothy D. SweemerCAOSell12,012$7.62$91,531.44View SEC Filing  
8/16/2017Timothy D. SweemerCAOSell15,488$7.82$121,116.16View SEC Filing  
7/20/2017Joseph J. SarretInsiderSell2,038$8.95$18,240.10View SEC Filing  
6/30/2017Life Sciences Maste PerceptiveMajor ShareholderBuy301,004$7.71$2,320,740.84View SEC Filing  
5/25/2017Perceptive Advisors LlcMajor ShareholderBuy1,902,400$6.25$11,890,000.00View SEC Filing  
5/19/2016Eric BjerkholtDirectorBuy24,500$3.64$89,180.00View SEC Filing  
5/12/2016David GreenwoodDirectorBuy3,000$3.58$10,740.003,000View SEC Filing  
2/25/2015Peter D StapleCEOBuy3,600$6.99$25,164.00View SEC Filing  
11/24/2014Robert S BreuilCFOBuy4,600$5.38$24,748.00View SEC Filing  
11/21/2014Peter D StapleCEOBuy9,000$5.34$48,060.00View SEC Filing  
8/27/2014Peter D StapleCEOBuy2,578$6.10$15,725.80View SEC Filing  
5/30/2014Peter D StapleCEOBuy7,200$7.04$50,688.00View SEC Filing  
4/8/2014Woodlands Health Venture EssexMajor ShareholderBuy400,000$8.00$3,200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Corium International (NASDAQ CORI) News Headlines

Source:
DateHeadline
Corium International (CORI) Expected to Post Quarterly Sales of $7.07 MillionCorium International (CORI) Expected to Post Quarterly Sales of $7.07 Million
www.americanbankingnews.com - April 18 at 4:14 AM
Corium International (CORI) Cut to Sell at Zacks Investment ResearchCorium International (CORI) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - April 16 at 8:40 PM
Corium International (CORI) Rating Lowered to Buy at BidaskClubCorium International (CORI) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 16 at 10:55 AM
Zacks: Brokerages Expect Corium International (CORI) to Post -$0.41 Earnings Per ShareZacks: Brokerages Expect Corium International (CORI) to Post -$0.41 Earnings Per Share
www.americanbankingnews.com - April 16 at 7:11 AM
Corium International (CORI) Downgraded by BidaskClubCorium International (CORI) Downgraded by BidaskClub
www.americanbankingnews.com - April 13 at 4:55 PM
Why the Earnings Streak Will Continue for Corium International (CORI)Why the Earnings Streak Will Continue for Corium International (CORI)
finance.yahoo.com - April 13 at 10:26 AM
CymaBay Therapeutics (CBAY) in Focus: Stock Moves 11.4% HigherCymaBay Therapeutics (CBAY) in Focus: Stock Moves 11.4% Higher
finance.yahoo.com - April 12 at 10:56 AM
Corium International (CORI) Receives Average Recommendation of "Buy" from BrokeragesCorium International (CORI) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 11 at 5:43 PM
Zacks Investment Research Lowers Corium International (CORI) to HoldZacks Investment Research Lowers Corium International (CORI) to Hold
www.americanbankingnews.com - April 5 at 8:30 PM
Corium International (CORI) Given a $10.00 Price Target by Jefferies Group AnalystsCorium International (CORI) Given a $10.00 Price Target by Jefferies Group Analysts
www.americanbankingnews.com - April 4 at 4:42 PM
Corium International (CORI) Lifted to "Buy" at ValuEngineCorium International (CORI) Lifted to "Buy" at ValuEngine
www.americanbankingnews.com - April 3 at 5:52 PM
Corium International (CORI) Upgraded to Buy by Zacks Investment ResearchCorium International (CORI) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 2 at 8:40 PM
Corium International (CORI) Expected to Announce Quarterly Sales of $7.07 MillionCorium International (CORI) Expected to Announce Quarterly Sales of $7.07 Million
www.americanbankingnews.com - April 1 at 4:20 AM
Corium International (CORI) Upgraded to "Hold" at ValuEngineCorium International (CORI) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - March 31 at 3:20 PM
Corium International (CORI) Downgraded by Zacks Investment Research to HoldCorium International (CORI) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 30 at 8:23 PM
Corium International (CORI) Expected to Announce Earnings of -$0.41 Per ShareCorium International (CORI) Expected to Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - March 30 at 9:22 AM
Corium International (CORI) Sees Significant Growth in Short InterestCorium International (CORI) Sees Significant Growth in Short Interest
www.americanbankingnews.com - March 30 at 3:38 AM
Cantor Fitzgerald Reiterates Buy Rating for Corium International (CORI)Cantor Fitzgerald Reiterates Buy Rating for Corium International (CORI)
www.americanbankingnews.com - March 27 at 9:10 PM
Corium International (CORI) Rating Increased to Buy at BidaskClubCorium International (CORI) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 26 at 11:30 PM
Corium International (CORI) Upgraded to "Hold" by ValuEngineCorium International (CORI) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - March 25 at 7:32 PM
Corium International (CORI) Cut to "Hold" at Zacks Investment ResearchCorium International (CORI) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 23 at 8:28 PM
Corium International (CORI) Stock Rating Upgraded by Zacks Investment ResearchCorium International (CORI) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 22 at 8:42 PM
Corium to Present at the 17th Annual Needham Healthcare ConferenceCorium to Present at the 17th Annual Needham Healthcare Conference
globenewswire.com - March 20 at 10:07 AM
Corium to Present at the 17th Annual Needham Healthcare Conference Corium to Present at the 17th Annual Needham Healthcare Conference 
finance.yahoo.com - March 19 at 10:08 AM
Corium International (CORI) Cut to "Hold" at BidaskClubCorium International (CORI) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - March 18 at 7:10 PM
Corium International Inc (CORI) Receives Average Recommendation of "Buy" from BrokeragesCorium International Inc (CORI) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 17 at 5:30 PM
$7.07 Million in Sales Expected for Corium International Inc (CORI) This Quarter$7.07 Million in Sales Expected for Corium International Inc (CORI) This Quarter
www.americanbankingnews.com - March 15 at 1:47 PM
Cantor Fitzgerald Comments on Corium International Incs FY2018 Earnings (CORI)Cantor Fitzgerald Comments on Corium International Inc's FY2018 Earnings (CORI)
www.americanbankingnews.com - March 14 at 10:07 AM
Corium International Inc (CORI) is Tamarack Advisers LPs 8th Largest PositionCorium International Inc (CORI) is Tamarack Advisers LP's 8th Largest Position
www.americanbankingnews.com - March 6 at 10:30 AM
AWM Investment Company Inc. Sells 31,557 Shares of Corium International Inc (CORI)AWM Investment Company Inc. Sells 31,557 Shares of Corium International Inc (CORI)
www.americanbankingnews.com - March 6 at 4:44 AM
BRIEF-RTW Investments Reports Passive Stake Of 5.29% In Corium InternationalBRIEF-RTW Investments Reports Passive Stake Of 5.29% In Corium International
www.reuters.com - March 5 at 4:35 PM
Corium International Inc (CORI) Stake Lessened by Royce & Associates LPCorium International Inc (CORI) Stake Lessened by Royce & Associates LP
www.americanbankingnews.com - March 5 at 11:09 AM
Emory University Acquires New Position in Corium International Inc (CORI)Emory University Acquires New Position in Corium International Inc (CORI)
www.americanbankingnews.com - March 4 at 3:02 PM
Corium International Inc (CORI) is Broadfin Capital LLCs 6th Largest PositionCorium International Inc (CORI) is Broadfin Capital LLC's 6th Largest Position
www.americanbankingnews.com - March 2 at 5:08 AM
Here's Why Corium International Sank TodayHere's Why Corium International Sank Today
finance.yahoo.com - March 1 at 4:22 PM
Corium Prices Offering of $100 Million of 5% Convertible Senior NotesCorium Prices Offering of $100 Million of 5% Convertible Senior Notes
finance.yahoo.com - March 1 at 9:38 AM
Corium Announces Proposed Offering of $100 Million of Convertible Senior Notes; Receives FDA Feedback on Pilot Bioequivalence StudyCorium Announces Proposed Offering of $100 Million of Convertible Senior Notes; Receives FDA Feedback on Pilot Bioequivalence Study
finance.yahoo.com - February 28 at 4:32 PM
Zacks: Analysts Anticipate Corium International Inc (CORI) Will Post Quarterly Sales of $7.07 MillionZacks: Analysts Anticipate Corium International Inc (CORI) Will Post Quarterly Sales of $7.07 Million
www.americanbankingnews.com - February 26 at 5:52 AM
Zacks: Brokerages Anticipate Corium International Inc (CORI) Will Post Earnings of -$0.41 Per ShareZacks: Brokerages Anticipate Corium International Inc (CORI) Will Post Earnings of -$0.41 Per Share
www.americanbankingnews.com - February 24 at 8:06 AM
Corium International Inc (CORI) Given Average Rating of "Buy" by BrokeragesCorium International Inc (CORI) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 20 at 5:32 PM
FY2018 EPS Estimates for Corium International Inc Raised by Cantor Fitzgerald (CORI)FY2018 EPS Estimates for Corium International Inc Raised by Cantor Fitzgerald (CORI)
www.americanbankingnews.com - February 14 at 11:24 AM
Corium International (CORI) PT Set at $14.00 by HC WainwrightCorium International (CORI) PT Set at $14.00 by HC Wainwright
www.americanbankingnews.com - February 10 at 4:44 PM
Corium Reports First Quarter Fiscal 2018 Financial Results and Corporate HighlightsCorium Reports First Quarter Fiscal 2018 Financial Results and Corporate Highlights
finance.yahoo.com - February 8 at 4:42 PM
Corium International Inc (CORI) Expected to Announce Earnings of -$0.43 Per ShareCorium International Inc (CORI) Expected to Announce Earnings of -$0.43 Per Share
www.americanbankingnews.com - February 7 at 9:52 AM
Corium to Present at Upcoming Healthcare Investor ConferencesCorium to Present at Upcoming Healthcare Investor Conferences
finance.yahoo.com - February 6 at 8:48 AM
Tetraphase Pharmaceuticals (TTPH) vs. Corium International (CORI) Financial AnalysisTetraphase Pharmaceuticals (TTPH) vs. Corium International (CORI) Financial Analysis
www.americanbankingnews.com - February 5 at 1:39 PM
Corium International (CORI) Lowered to "Hold" at BidaskClubCorium International (CORI) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - February 3 at 11:58 AM
Corium to Report First Quarter Fiscal 2018 Financial Results on Thursday, February 8, 2018Corium to Report First Quarter Fiscal 2018 Financial Results on Thursday, February 8, 2018
finance.yahoo.com - February 1 at 4:46 PM
Head to Head Review: Corium International (CORI) and Novo Nordisk A/S (NVO)Head to Head Review: Corium International (CORI) and Novo Nordisk A/S (NVO)
www.americanbankingnews.com - January 31 at 9:12 PM
3 Hot Insider Biotech Stocks You Need to Know3 Hot Insider Biotech Stocks You Need to Know
www.nasdaq.com - January 29 at 8:54 AM

SEC Filings

Corium International (NASDAQ:CORI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Corium International (NASDAQ:CORI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Corium International (NASDAQ CORI) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.